1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Pipeline Review, H2 2020, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.
Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 23 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.
Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAspergillosis - Overview
Aspergillosis - Therapeutics Development
Aspergillosis - Therapeutics Assessment
Aspergillosis - Companies Involved in Therapeutics Development
Aspergillosis - Drug Profiles
Aspergillosis - Dormant Projects
Aspergillosis - Discontinued Products
Aspergillosis - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Aspergillosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Aspergillosis - Pipeline by ABIONYX Pharma SA, H2 2020
- Aspergillosis - Pipeline by Acea Biotech Inc, H2 2020
- Aspergillosis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2020
- Aspergillosis - Pipeline by Argenx SE, H2 2020
- Aspergillosis - Pipeline by Basilea Pharmaceutica Ltd, H2 2020
- Aspergillosis - Pipeline by Bio-Synectics Inc, H2 2020
- Aspergillosis - Pipeline by Biosergen AS, H2 2020
- Aspergillosis - Pipeline by Cidara Therapeutics Inc, H2 2020
- Aspergillosis - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2020
- Aspergillosis - Pipeline by F2G Ltd, H2 2020
- Aspergillosis - Pipeline by Galephar Pharmaceutical Research Inc, H2 2020
- Aspergillosis - Pipeline by iCo Therapeutics Inc, H2 2020
- Aspergillosis - Pipeline by Immupharma Plc, H2 2020
- Aspergillosis - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H2 2020
- Aspergillosis - Pipeline by Matinas BioPharma Holdings Inc, H2 2020
- Aspergillosis - Pipeline by Merck & Co Inc, H2 2020
- Aspergillosis - Pipeline by Molecular Express Inc, H2 2020
- Aspergillosis - Pipeline by Mycovia Pharmaceuticals Inc, H2 2020
- Aspergillosis - Pipeline by Zambon Co SpA, H2 2020
- Aspergillosis - Dormant Projects, H2 2020
- Aspergillosis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Aspergillosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ABIONYX Pharma SA
- Acea Biotech Inc
- Amplyx Pharmaceuticals Inc
- Argenx SE
- Basilea Pharmaceutica Ltd
- Bio-Synectics Inc
- Biosergen AS
- Cidara Therapeutics Inc
- CSPC Pharmaceutical Group Ltd
- F2G Ltd
- Galephar Pharmaceutical Research Inc
- iCo Therapeutics Inc
- Immupharma Plc
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Matinas BioPharma Holdings Inc
- Merck & Co Inc
- Molecular Express Inc
- Mycovia Pharmaceuticals Inc
- Nanomerics Ltd
- Novabiotics Ltd
- Pulmocide Ltd
- Pulmonomy Inc
- Regeneron Pharmaceuticals Inc
- Scynexis Inc
- Sealife PHARMA GMBH
- Shaanxi Synthetic Pharmaceutical Co Ltd
- TFF Pharmaceuticals Inc
- Trilogy Therapeutics Inc
- Visterra Inc
- Zambon Co SpA
